register

Market Research & Insights

The changing landscape of Research and Development

Health Industry Hub | September 25, 2019 |

Over the past decade, the development of innovative medicines has changed dramatically. This IQVIA report evaluates research and development (R&D) activity and landscape, clinical development process productivity levels, and how key trial trends will reshape clinical development over the next five years. The characteristics and development path of both newly launched therapies and pipeline therapies are examined along with the company transitions that bring these drugs to the market. This report presents a proprietary index of clinical development productivity reflecting changes in the complexity, success and duration of trials over time.

Key findings

  1. Of the new active substances launched in 2018, 46% were approved based on data from trials with fewer than 500 total subjects
  2. Emerging biopharma companies now account for over 70% of the total late stage R&D pipeline
  3. Composite success rates varied by therapy area between 6−15% in 2018, with rates for rare diseases and GI/NASH exceeding averages
  4. Eight key trends are influencing aspects of trial design, duration and success
  5. Biomarkers will have the greatest impact on clinical productivity yielding a 34% average increase across all phases of development

Source: www.iqvia.com


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.